Biotechs Need To Work Harder To Grab What Capital Remains, E&Y Reports
Executive Summary
Biotechs fared better than expected in 2009, but the market still is not healthy. In the U.S., 20 percent of companies raised 78.5 percent of the capital, widening the already vast gap between the "have" and "have nots," Ernst & Young notes in its annual Beyond Borders report
You may also be interested in...
Biotechs Need To Be More Differentiated To Succeed, E&Y Reports
The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011